The new ATU programme may support more efficient use of healthcare spending but could it mean fewer patients receive early access to treatments? Here, experts from Charles River Associates discuss the new ATU programme reforms and how they could impact pharma.
List view / Grid view
Haute Autorité de Santé (HAS)
Pharmaceutical companies are sponsoring a project to generate, align and share disease-level data across an entire condition for health technology assessments...